Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig - PubMed (original) (raw)
Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig
David Moses et al. Neuropharmacology. 2004 Jul.
Abstract
The modification of L-3,4-dihydrooxyphenylalanine- (L-DOPA-) induced turning response by the new selective monoamine oxidase type B (MAO-B) inhibitor rasagiline was studied in guinea-pigs bearing a unilateral 6-hydroxydopamine-induced lesion in the substantia nigra. In an initial experiment, it was established that contralateral turning is induced in lesioned guinea-pigs in response to apomorphine (18 mg/kg i.p.) and L-DOPA/carbidopa (15/3.5 mg/kg i.p.), while ipsilateral turning is induced by S(+)-methamphetamine (7 mg/kg i.p.). The effect of rasagiline was studied in a chronic treatment regimen, in which animals were treated with rasagiline (0.05 mg/kg s.c.) or saline s.c. daily commencing 2 weeks after lesioning, and L-DOPA/carbidopa (4:1 mg/kg) was administered once daily for 21 days. Only guinea-pigs with 95% or more depletion of striatal dopamine were included in this study. Guinea-pigs treated with rasagiline had a significantly increased intensity and duration of turning in response to L-DOPA (P <0.05 by repeated measures ANOVA) over the 21-day period. On day 21, turning averaged 806+/-105 (n=10) vs 442+/-123 (n=11) turns per 180 min for rasagiline and vehicle treated animals, respectively (P <0.05); turning duration half-time averaged 81+/-15.4 (n=10) as opposed to 33+/-7.6 (n=11) min for rasagiline and vehicle treatments (P <0.01). Concentration of dopamine in intact striatum was significantly increased (69.3+/-2.1 and 60.3+/-2.4 pmol/mg tissue for rasagiline and vehicle, P <0.05) and levels of dihydroxyphenylacetic acid and homovanillic acid were decreased by the rasagiline treatment. Activity of brain MAO-B was 8.6+/-2.9% and MAO-A was 71+/-1.5% that of control in rasagiline-treated animals. Chronic, selective inhibition of MAO-B by rasagiline potentiated L-DOPA-induced turning in this rodent model.
Similar articles
- Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Blandini F, et al. Exp Neurol. 2004 Jun;187(2):455-9. doi: 10.1016/j.expneurol.2004.03.005. Exp Neurol. 2004. PMID: 15144871 - Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR. Guay DR. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. doi: 10.1016/j.amjopharm.2006.12.001. Am J Geriatr Pharmacother. 2006. PMID: 17296539 Review. - Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A, Fenu S, Morelli M. Pinna A, et al. Synapse. 2001 Mar 1;39(3):233-8. doi: 10.1002/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K. Synapse. 2001. PMID: 11284438 - Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH. Kupsch A, et al. J Neural Transm (Vienna). 2001;108(8-9):985-1009. doi: 10.1007/s007020170018. J Neural Transm (Vienna). 2001. PMID: 11716151 - Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ, Swope DM, Dashtipour K. Chen JJ, et al. Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021. Clin Ther. 2007. PMID: 18035186 Review.
Cited by
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Modification of L-DOPA pharmacological activity by MAO inhibitors.
Finberg JP, Sader-Mazbar O. Finberg JP, et al. J Neural Transm (Vienna). 2007;114(6):801-5. doi: 10.1007/s00702-007-0691-y. Epub 2007 Apr 10. J Neural Transm (Vienna). 2007. PMID: 17417741 - The 6-hydroxydopamine model of Parkinson's disease.
Simola N, Morelli M, Carta AR. Simola N, et al. Neurotox Res. 2007 Apr;11(3-4):151-67. doi: 10.1007/BF03033565. Neurotox Res. 2007. PMID: 17449457 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources